Anterior Cingulate Cortex Glutamate Levels and Sensory Integration Are Associated in Individuals With Social Anhedonia: A Comparison Between 3T and 7T MRS

Abstract

Deficits in schizophrenia are linked to abnormalities in the glutamate (Glu) system, which are believed to result in neurological soft signs (NSS) and negative symptoms. This study investigated the relationship between Glu levels of the anterior cingulate cortex (ACC) and NSS, particularly sensory integration, in individuals with high and low levels of social anhedonia using 3 Tesla (T) and 7T Magnetic Resonance Spectroscopy (MRS). We recruited 16 participants with high social anhedonia and 18 with low social anhedonia and correlated their NSS scores with ACC Glu levels. While spectral quality metrics differed between field strengths, with 7T showing better spectral resolution and metabolite quantification reliability, both 3T and 7T data showed consistent correlation patterns. Our findings demonstrated that higher ACC Glu levels were associated with poorer sensory integration in high levels of social anhedonia across both field strengths, supported by both Pearson and Spearman rank correlations. Notably, the opposite pattern of association was found in people with low levels of social anhedonia at 7T. The Glu systems may be the common mechanisms for negative symptoms and NSS, highlighting its potential as a therapeutic target.

Keywords

anhedonia / glutamate / magnetic resonance spectroscopy / neurological soft signs / schizotypy

References

[1] Barch, D. M., C. S. Carter, T. S. Braver, et al. 2001. “Selective Deficits in Prefrontal Cortex Function in Medication-Naive Patients With Schizophrenia.” Archives of General Psychiatry 58, no. 3: 280-288. https://doi.org/10.1001/archpsyc.58.3.280.

[2] Blanchard, J. L., W. P. Horan, and S. A. Brown. 2001. “Diagnostic Differences in Social Anhedonia: A Longitudinal Study of Schizophrenia and Major Depressive Disorder.” Journal of Abnormal Psychology 110, no. 3: 363-371. https://doi.org/10.1037/0021-843X.110.3.363.

[3] Bombin, I., C. Arango, and R. W. Buchanan. 2005. “Significance and Meaning of Neurological Signs in Schizophrenia: Two Decades Later.” Schizophrenia Bulletin 31, no. 4: 962-977. https://doi.org/10.1093/schbul/sbi028.

[4] Bossong, M. G., M. Antoniades, M. Azis, et al. 2019. “Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.” JAMA Psychiatry 76, no. 2: 199-207. https://doi.org/10.1001/jamapsychiatry.2018.3252.

[5] Brandt, A. S., P. G. Unschuld, S. Pradhan, et al. 2016. “Age-Related Changes in Anterior Cingulate Cortex Glutamate in Schizophrenia: A (1)H MRS Study at 7 Tesla.” Schizophrenia Research 172, no. 1-3: 101-105. https://doi.org/10.1016/j.schres.2016.02.017.

[6] Cai, X.-L., G.-Y. Li, L.-L. Wang, et al. 2022. “Striatal GABA Level Is Associated With Sensory Integration Ability in Individuals With Low Levels of Negative Schizotypy.” PsyCh Journal 11, no. 2: 205-213. https://doi.org/10.1002/pchj.479.

[7] Cai, X. L., C. C. Pu, S. Z. Zhou, et al. 2023. “Anterior Cingulate Glutamate Levels Associate With Functional Activation and Connectivity During Sensory Integration in Schizophrenia: A Multimodal (1)H-MRS and fMRI Study.” Psychological Medicine 53, no. 11: 4904-4914. https://doi.org/10.1017/S0033291722001817.

[8] Cai, X. L., Y. M. Wang, Y. Wang, et al. 2021. “Neurological Soft Signs Are Associated With Altered Cerebellar-Cerebral Functional Connectivity in Schizophrenia.” Schizophrenia Bulletin 47, no. 5: 1452-1462. https://doi.org/10.1093/schbul/sbaa200.

[9] Cai, X. L., M. Weigl, B. H. Liu, E. F. C. Cheung, J. H. Ding, and R. C. K. Chan. 2019. “Delay Discounting and Affective Priming in Individuals With Negative Schizotypy.” Schizophrenia Research 210: 180-187. https://doi.org/10.1016/j.schres.2018.12.040.

[10] Chan, R. C., and I. I. Gottesman. 2008. “Neurological Soft Signs as Candidate Endophenotypes for Schizophrenia: A Shooting Star or a Northern Star?” Neuroscience and Biobehavioral Reviews 32, no. 5: 957-971. https://doi.org/10.1016/j.neubiorev.2008.01.005.

[11] Chan, R. C., H. S. Shi, F. L. Geng, et al. 2015. “The Chapman Psychosis-Proneness Scales: Consistency Across Culture and Time.” Psychiatry Research 228, no. 1: 143-149. https://doi.org/10.1016/j.psychres.2015.04.031.

[12] Chan, R. C., L. L. Wang, J. Huang, Y. Wang, and S. S. Lui. 2025. “Anhedonia Across and Beyond the Schizophrenia Spectrum.” Schizophrenia Bulletin 51, no. 2: 293-308. https://doi.org/10.1093/schbul/sbae165.

[13] Chan, R. C., Y. Wang, L. Wang, et al. 2009. “Neurological Soft Signs and Their Relationships to Neurocognitive Functions: A Re-Visit With the Structural Equation Modeling Design.” PLoS One 4, no. 12: e8469. https://doi.org/10.1371/journal.pone.0008469.

[14] Chan, R. C., Y. Wang, C. Yan, et al. 2012. “A Study of Trait Anhedonia in Non-Clinical Chinese Samples: Evidence From the Chapman Scales for Physical and Social Anhedonia.” PLoS One 7, no. 4: e34275. https://doi.org/10.1371/journal.pone.0034275.

[15] Chan, R. C., W. Xie, F. L. Geng, et al. 2016. “Clinical Utility and Lifespan Profiling of Neurological Soft Signs in Schizophrenia Spectrum Disorders.” Schizophrenia Bulletin 42, no. 3: 560-570. https://doi.org/10.1093/schbul/sbv196.

[16] Chan, R. C., T. Xu, R. W. Heinrichs, Y. Yu, and Y. Wang. 2010. “Neurological Soft Signs in Schizophrenia: A Meta-Analysis.” Schizophrenia Bulletin 36, no. 6: 1089-1104. https://doi.org/10.1093/schbul/sbp011.

[17] Chan, R. C. K., H. R. Cui, M. Y. Chu, et al. 2018. “Neurological Soft Signs Precede the Onset of Schizophrenia: A Study of Individuals With Schizotypy, Ultra-High-Risk Individuals, and First-Onset Schizophrenia.” European Archives of Psychiatry and Clinical Neuroscience 268, no. 1: 49-56. https://doi.org/10.1007/s00406-017-0828-4.

[18] Chan, R. C. K., F. L. Geng, S. S. Y. Lui, et al. 2015. “Course of Neurological Soft Signs in First-Episode Schizophrenia: Relationship With Negative Symptoms and Cognitive Performances.” Scientific Reports 5: 11053. https://doi.org/10.1038/srep11053.

[19] Chapman, L. J., J. P. Chapman, and M. L. Raulin. 1976. “Scales for Physical and Social Anhedonia.” Journal of Abnormal Psychology 85, no. 4: 374-382. https://doi.org/10.1037//0021-843x.85.4.374.

[20] Chen, E. Y., J. Shapleske, R. Luque, et al. 1995. “The Cambridge Neurological Inventory: A Clinical Instrument for Assessment of Soft Neurological Signs in Psychiatric Patients.” Psychiatry Research 56, no. 2: 183-204. https://doi.org/10.1016/0165-1781(95)02535-2.

[21] Chen, S. Y., L. L. Wang, G. Y. Li, et al. 2022. “Glutamate Correlates Negatively With Cognitive Theory of Mind in Schizotypy.” PsyCh Journal 11, no. 3: 356-358. https://doi.org/10.1002/pchj.503.

[22] Chun, C. A., L. Ciceron, and T. R. Kwapil. 2018. “A Meta-Analysis of Context Integration Deficits Across the Schizotypy Spectrum Using AX-CPT and DPX Tasks.” Journal of Abnormal Psychology 127, no. 8: 789-806. https://doi.org/10.1037/abn0000383.

[23] Cicero, D. C., K. G. Jonas, K. Li, G. Perlman, and R. Kotov. 2019. “Common Taxonomy of Traits and Symptoms: Linking Schizophrenia Symptoms, Schizotypy, and Normal Personality.” Schizophrenia Bulletin 45, no. 6: 1336-1348. https://doi.org/10.1093/schbul/sbz005.

[24] Cloke, J. M., R. Nguyen, B. Y. Chung, et al. 2016. “A Novel Multisensory Integration Task Reveals Robust Deficits in Rodent Models of Schizophrenia: Converging Evidence for Remediation via Nicotinic Receptor Stimulation of Inhibitory Transmission in the Prefrontal Cortex.” Journal of Neuroscience 36, no. 50: 12570-12585. https://doi.org/10.1523/JNEUROSCI.1628-16.2016.

[25] Cloke, J. M., and B. D. Winters. 2015. “Alpha(4)beta(2) Nicotinic Receptor Stimulation of the GABAergic System Within the Orbitofrontal Cortex Ameliorates the Severe Crossmodal Object Recognition Impairment in Ketamine-Treated Rats: Implications for Cognitive Dysfunction in Schizophrenia.” Neuropharmacology 90: 42-52. https://doi.org/10.1016/j.neuropharm.2014.11.004.

[26] Correll, C. U., and N. R. Schooler. 2020. “Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment.” Neuropsychiatric Disease and Treatment 16: 519-534. https://doi.org/10.2147/NDT.S225643.

[27] de Bartolomeis, A., E. Prinzivalli, G. Callovini, et al. 2018. “Treatment Resistant Schizophrenia and Neurological Soft Signs May Converge on the Same Pathology: Evidence From Explanatory Analysis on Clinical, Psychopathological, and Cognitive Variables.” Progress in Neuro-Psychopharmacology and Biological Psychiatry 81: 356-366. https://doi.org/10.1016/j.pnpbp.2017.09.002.

[28] Feng, Y., Z. Wang, G. Lin, et al. 2020. “Neurological Soft Signs and Neurocognitive Deficits in Remitted Patients With Schizophrenia, Their First-Degree Unaffected Relatives, and Healthy Controls.” European Archives of Psychiatry and Clinical Neuroscience 270, no. 3: 383-391. https://doi.org/10.1007/s00406-019-01024-x.

[29] Fong, T. C., R. T. Ho, A. H. Wan, and F. S. Au-Yeung. 2017. “Psychiatric Symptoms Mediate the Effects of Neurological Soft Signs on Functional Outcomes in Patients With Chronic Schizophrenia: A Longitudinal Path-Analytic Study.” Psychiatry Research 249: 152-158. https://doi.org/10.1016/j.psychres.2017.01.023.

[30] Galderisi, S., A. Mucci, S. Dollfus, et al. 2021. “EPA Guidance on Assessment of Negative Symptoms in Schizophrenia.” European Psychiatry 64, no. 1: e23. https://doi.org/10.1192/j.eurpsy.2021.11.

[31] Gao, R., and P. Penzes. 2015. “Common Mechanisms of Excitatory and Inhibitory Imbalance in Schizophrenia and Autism Spectrum Disorders.” Current Molecular Medicine 15, no. 2: 146-167. https://doi.org/10.2174/1566524015666150303003028.

[32] Goldsmith, D. R., and M. H. Rapaport. 2020. “Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits.” Frontiers in Psychiatry 11: 46. https://doi.org/10.3389/fpsyt.2020.00046.

[33] Grent-'t-Jong, T., R. Gajwani, J. Gross, et al. 2022. “MR-Spectroscopy of GABA and Glutamate/Glutamine Concentrations in Auditory Cortex in Clinical High-Risk for Psychosis Individuals.” Frontiers in Psychiatry 13: 859322. https://doi.org/10.3389/fpsyt.2022.859322.

[34] Heinrichs, D. W., and R. W. Buchanan. 1988. “Significance and Meaning of Neurological Signs in Schizophrenia.” American Journal of Psychiatry 145, no. 1: 11-18. https://doi.org/10.1176/ajp.145.1.11.

[35] Howes, O. D., R. McCutcheon, M. J. Owen, and R. M. Murray. 2017. “The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.” Biological Psychiatry 81, no. 1: 9-20. https://doi.org/10.1016/j.biopsych.2016.07.014.

[36] Iasevoli, F., C. Avagliano, B. Altavilla, et al. 2018. “Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs.” Frontiers in Psychiatry 9: 553. https://doi.org/10.3389/fpsyt.2018.00553.

[37] Jacklin, D. L., A. Goel, K. J. Clementino, A. W. Hall, J. C. Talpos, and B. D. Winters. 2012. “Severe Cross-Modal Object Recognition Deficits in Rats Treated Sub-Chronically With NMDA Receptor Antagonists Are Reversed by Systemic Nicotine: Implications for Abnormal Multisensory Integration in Schizophrenia.” Neuropsychopharmacology 37, no. 10: 2322-2331. https://doi.org/10.1038/npp.2012.84.

[38] Javitt, D. C.2015. “Meeting Overview: Sensory Perception and Schizophrenia, Lausanne, Switzerland June 31-July 1, 2014.” Schizophrenia Research: Cognition 2, no. 2: 42-45. https://doi.org/10.1016/j.scog.2015.04.003.

[39] Javitt, D. C., and R. Freedman. 2015. “Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia.” American Journal of Psychiatry 172, no. 1: 17-31. https://doi.org/10.1176/appi.ajp.2014.13121691.

[40] Johns, L. C., and J. Van Os. 2001. “The Continuity of Psychotic Experiences in the General Population.” Clinical Psychology Review 21, no. 8: 1125-1141. https://doi.org/10.1016/s0272-7358(01)00103-9.

[41] Kruse, A. O., and J. R. Bustillo. 2022. “Glutamatergic Dysfunction in Schizophrenia.” Translational Psychiatry 12, no. 1: 500. https://doi.org/10.1038/s41398-022-02253-w.

[42] Ladd, M. E., P. Bachert, M. Meyerspeer, et al. 2018. “Pros and Cons of Ultra-High-Field MRI/MRS for Human Application.” Progress in Nuclear Magnetic Resonance Spectroscopy 109: 1-50. https://doi.org/10.1016/j.pnmrs.2018.06.001.

[43] Laruelle, M.2014. “Schizophrenia: From Dopaminergic to Glutamatergic Interventions.” Current Opinion in Pharmacology 14: 97-102. https://doi.org/10.1016/j.coph.2014.01.001.

[44] Liang, S., Y. Wu, L. Hanxiaoran, A. J. Greenshaw, and T. Li. 2022. “Anhedonia in Depression and Schizophrenia: Brain Reward and Aversion Circuits.” Neuropsychiatric Disease and Treatment 18: 1385-1396. https://doi.org/10.2147/NDT.S367839.

[45] Marsman, A., M. P. van den Heuvel, D. W. Klomp, R. S. Kahn, P. R. Luijten, and H. E. Hulshoff Pol. 2013. “Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies.” Schizophrenia Bulletin 39, no. 1: 120-129. https://doi.org/10.1093/schbul/sbr069.

[46] McCarthy, L., G. Verma, G. Hangel, et al. 2022. “Application of 7T MRS to High-Grade Gliomas.” American Journal of Neuroradiology 43, no. 10: 1378-1395. https://doi.org/10.3174/ajnr.A7502.

[47] Meehl, P.1962. “Schizophrenia, Schizotypy and Schizotaxia.” American Journal of Psychology 17: 827-838. https://doi.org/10.1037/h0041029.

[48] Merritt, K., P. K. McGuire, A. Egerton, et al. 2021. “Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-Analysis of Individual Participant-Level Data.” JAMA Psychiatry 78, no. 6: 667-681. https://doi.org/10.1001/jamapsychiatry.2021.0380.

[49] Millan, M. J., K. Fone, T. Steckler, and W. P. Horan. 2014. “Negative Symptoms of Schizophrenia: Clinical Characteristics, Pathophysiological Substrates, Experimental Models and Prospects for Improved Treatment.” European Neuropsychopharmacology 24, no. 5: 645-692. https://doi.org/10.1016/j.euroneuro.2014.03.008.

[50] Mittal, V. A., D. J. Dean, J. A. Bernard, et al. 2014. “Neurological Soft Signs Predict Abnormal Cerebellar-Thalamic Tract Development and Negative Symptoms in Adolescents at High Risk for Psychosis: A Longitudinal Perspective.” Schizophrenia Bulletin 40, no. 6: 1204-1215. https://doi.org/10.1093/schbul/sbt199.

[51] Miyamoto, S., N. Miyake, L. F. Jarskog, W. W. Fleischhacker, and J. A. Lieberman. 2012. “Pharmacological Treatment of Schizophrenia: A Critical Review of the Pharmacology and Clinical Effects of Current and Future Therapeutic Agents.” Molecular Psychiatry 17, no. 12: 1206-1227. https://doi.org/10.1038/mp.2012.47.

[52] Modinos, G., A. McLaughlin, A. Egerton, et al. 2017. “Corticolimbic Hyper-Response to Emotion and Glutamatergic Function in People With High Schizotypy: A Multimodal fMRI-MRS Study.” Translational Psychiatry 7, no. 4: e1083. https://doi.org/10.1038/tp.2017.53.

[53] Oeltzschner, G., H. J. Zollner, S. C. N. Hui, et al. 2020. “Osprey: Open-Source Processing, Reconstruction & Estimation of Magnetic Resonance Spectroscopy Data.” Journal of Neuroscience Methods 343: 108827. https://doi.org/10.1016/j.jneumeth.2020.108827.

[54] Pelizza, L., and A. Ferrari. 2009. “Anhedonia in Schizophrenia and Major Depression: State or Trait?” Annals of General Psychiatry 8: 1-9. https://doi.org/10.1186/1744-859X-8-222009.

[55] Poels, E. M., L. S. Kegeles, J. T. Kantrowitz, et al. 2014. “Imaging Glutamate in Schizophrenia: Review of Findings and Implications for Drug Discovery.” Molecular Psychiatry 19, no. 1: 20-29. https://doi.org/10.1038/mp.2013.136.

[56] Pradhan, S., S. Bonekamp, J. S. Gillen, et al. 2015. “Comparison of Single Voxel Brain MRS AT 3 T and 7 T Using 32-Channel Head Coils.” Magnetic Resonance Imaging 33, no. 8: 1013-1018. https://doi.org/10.1016/j.mri.2015.06.003.

[57] R Core Team. 2023. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. https://www.R-project.org/.

[58] Raine, A.1991. “The SPQ: A Scale for the Assessment of Schizotypal Personality Based on DSM-III-R Criteria.” Schizophrenia Bulletin 17, no. 4: 555-564. https://doi.org/10.1093/schbul/17.4.555.

[59] Ramadan, S., A. Lin, and P. Stanwell. 2013. “Glutamate and Glutamine: A Review of In Vivo MRS in the Human Brain.” NMR in Biomedicine 26, no. 12: 1630-1646. https://doi.org/10.1002/nbm.3045.

[60] Rowland, L. M., A. Summerfelt, S. A. Wijtenburg, et al. 2016. “Frontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia.” JAMA Psychiatry 73, no. 2: 166-174. https://doi.org/10.1001/jamapsychiatry.2015.2680.

[61] Sanaei Nezhad, F., A. Anton, E. Michou, J. Jung, L. M. Parkes, and S. R. Williams. 2018. “Quantification of GABA, Glutamate and Glutamine in a Single Measurement at 3 T Using GABA-Edited MEGA-PRESS.” NMR in Biomedicine 31, no. 1: e3847. https://doi.org/10.1002/nbm.3847.

[62] Sheehan, D. V., Y. Lecrubier, K. H. Sheehan, et al. 1998. “The Mini-International Neuropsychiatric Interview (MINI): The Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10.” Journal of Clinical Psychiatry 59, no. 20: 22-33.

[63] Stanley, J. A., and N. Raz. 2018. “Functional Magnetic Resonance Spectroscopy: The ‘New’ MRS for Cognitive Neuroscience and Psychiatry Research.” Frontiers in Psychiatry 9: 76. https://doi.org/10.3389/fpsyt.2018.00076.

[64] Strube, W., L. Marshall, G. Quattrocchi, et al. 2020. “Glutamatergic Contribution to Probabilistic Reasoning and Jumping to Conclusions in Schizophrenia: A Double-Blind, Randomized Experimental Trial.” Biological Psychiatry 88, no. 9: 687-697. https://doi.org/10.1016/j.biopsych.2020.03.018.

[65] Tayoshi, S., S. Sumitani, K. Taniguchi, et al. 2009. “Metabolite Changes and Gender Differences in Schizophrenia Using 3-Tesla Proton Magnetic Resonance Spectroscopy (1H-MRS).” Schizophrenia Research 108, no. 1-3: 69-77. https://doi.org/10.1016/j.schres.2008.11.014.

[66] Umbricht, D., R. Koller, F. X. Vollenweider, and L. Schmid. 2002. “Mismatch Negativity Predicts Psychotic Experiences Induced by NMDA Receptor Antagonist in Healthy Volunteers.” Biological Psychiatry 51, no. 5: 400-406. https://doi.org/10.1016/s0006-3223(01)01242-2.

[67] van Os, J., B. P. Rutten, and R. Poulton. 2008. “Gene-Environment Interactions in Schizophrenia: Review of Epidemiological Findings and Future Directions.” Schizophrenia Bulletin 34, no. 6: 1066-1082. https://doi.org/10.1093/schbul/sbn117.

[68] Walther, S., and W. Strik. 2012. “Motor Symptoms and Schizophrenia.” Neuropsychobiology 66, no. 2: 77-92. https://doi.org/10.1159/000339456.

[69] Wang, L. L., Y. Gao, C. Yan, et al. 2025. “Characterizing the Profile of Anhedonia in Individuals With Schizotypal Traits, Subthreshold Depression and Autistic Traits.” PsyCh Journal 14, no. 3: 328-336. https://doi.org/10.1002/pchj.827.

[70] Wang, L. L., S. S. Lui, and R. C. Chan. 2024. “Neuropsychology and Neurobiology of Negative Schizotypy: A Selective Review.” Biological Psychiatry Global Open Science 4, no. 4: 100317. https://doi.org/10.1016/j.bpsgos.2024.100317.

[71] Wang, Y., W. H. Liu, Z. Li, et al. 2016. “Altered Corticostriatal Functional Connectivity in Individuals With High Social Anhedonia.” Psychological Medicine 46, no. 1: 125-135. https://doi.org/10.1017/S0033291715001592.

[72] Xu, T., Y. Wang, Z. Li, et al. 2016. “Heritability and Familiality of Neurological Soft Signs: Evidence From Healthy Twins, Patients With Schizophrenia and Non-Psychotic First-Degree Relatives.” Psychological Medicine 46, no. 1: 117-123. https://doi.org/10.1017/S0033291715001580.

[73] Yang, X., Y. Guo, P. Harrison, and X. Liu. 2022. “Social and General Anhedonia in Adolescents: Stability and Associations With Other Symptoms.” Journal of Adolescence 94, no. 3: 380-389. https://doi.org/10.1002/jad.12029.

[74] Zhang, Y. J., H. X. Hu, L. L. Wang, et al. 2023. “Altered Neural Mechanism of Social Reward Anticipation in Individuals With Schizophrenia and Social Anhedonia.” European Archives of Psychiatry and Clinical Neuroscience 273, no. 5: 1029-1039. https://doi.org/10.1007/s00406-022-01505-6.

[75] Zhao, Q., Z. Li, J. Huang, et al. 2014. “Neurological Soft Signs Are Not ‘Soft’ in Brain Structure and Functional Networks: Evidence From ALE Meta-Analysis.” Schizophrenia Bulletin 40, no. 3: 626-641. https://doi.org/10.1093/schbul/sbt063.

RIGHTS & PERMISSIONS

2025 The Author(s). PsyCh Journal published by Institute of Psychology, Chinese Academy of Sciences and John Wiley & Sons Australia, Ltd.